Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors

Next Previous
Trial Profile

Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Adenocarcinoma; Adrenal cancer; Advanced breast cancer; Anal cancer; Bladder cancer; Breast cancer; Cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Clear cell sarcoma; Endometrial cancer; Fallopian tube cancer; Fibrosarcoma; Gallbladder cancer; Haemangioblastoma; Haemangiosarcoma; Hepatoblastoma; Intestinal cancer; Kaposi's sarcoma; Leiomyosarcoma; Mesothelioma; Nasopharyngeal cancer; Neuroblastoma; Neuroectodermal tumours; Neuroendocrine tumours; Neurofibrosarcoma; Osteosarcoma; Ovarian cancer; Parathyroid cancer; Penile cancer; Renal cancer; Salivary gland cancer; Soft tissue sarcoma; Thyroid cancer; Tracheal neoplasms; Trophoblastic tumour; Urethral cancer; Yolk sac tumour
  • Focus Therapeutic Use
  • Acronyms ANTARES

Most Recent Events

  • 28 May 2025 Status changed from recruiting to active, no longer recruiting.
  • 20 Oct 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top